Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer

NCT03867045 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Study deemed non-essential under COVID pandemic,

Conditions

Metastatic Renal Cell Carcinoma Treated With Cabozantinib

Interventions

DEVICE: Usability of an electronic symptom management application

Sponsor

Duke University

Collaborators

[object Object]